EA201790892A1 - Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина - Google Patents

Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина

Info

Publication number
EA201790892A1
EA201790892A1 EA201790892A EA201790892A EA201790892A1 EA 201790892 A1 EA201790892 A1 EA 201790892A1 EA 201790892 A EA201790892 A EA 201790892A EA 201790892 A EA201790892 A EA 201790892A EA 201790892 A1 EA201790892 A1 EA 201790892A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methilpiperazin
dimethylphosphoril
chlor
pyrimidin
piperidin
Prior art date
Application number
EA201790892A
Other languages
English (en)
Other versions
EA035145B1 (ru
Inventor
Леонард В. Розамус
Прадип Шарма
Original Assignee
Ариад Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54365447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790892(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ариад Фармасьютикалз, Инк. filed Critical Ариад Фармасьютикалз, Инк.
Publication of EA201790892A1 publication Critical patent/EA201790892A1/ru
Publication of EA035145B1 publication Critical patent/EA035145B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/025—Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

В настоящем документе описаны кристаллические формы бригатиниба, содержащие их фармацевтические композиции и способы их получения и применения.
EA201790892A 2014-10-21 2015-10-21 Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]фенил}пиримидин-2,4-диамина EA035145B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066849P 2014-10-21 2014-10-21
PCT/US2015/056701 WO2016065028A1 (en) 2014-10-21 2015-10-21 Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine

Publications (2)

Publication Number Publication Date
EA201790892A1 true EA201790892A1 (ru) 2018-03-30
EA035145B1 EA035145B1 (ru) 2020-05-06

Family

ID=54365447

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790892A EA035145B1 (ru) 2014-10-21 2015-10-21 Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]фенил}пиримидин-2,4-диамина

Country Status (32)

Country Link
US (4) US10385078B2 (ru)
EP (2) EP3209647B1 (ru)
JP (2) JP6633072B2 (ru)
KR (2) KR102331856B1 (ru)
CN (3) CN111825717A (ru)
AU (1) AU2015335950B2 (ru)
CA (1) CA2965169C (ru)
CL (1) CL2017000979A1 (ru)
CO (1) CO2017004714A2 (ru)
CR (1) CR20170146A (ru)
CY (1) CY1123295T1 (ru)
DK (1) DK3209647T3 (ru)
DO (1) DOP2017000101A (ru)
EA (1) EA035145B1 (ru)
EC (1) ECSP17030878A (ru)
ES (1) ES2813726T3 (ru)
HR (1) HRP20201343T1 (ru)
HU (1) HUE051693T2 (ru)
IL (2) IL251818B (ru)
LT (1) LT3209647T (ru)
MX (1) MX2017005120A (ru)
MY (1) MY192216A (ru)
PE (1) PE20171344A1 (ru)
PH (1) PH12017500732A1 (ru)
PT (1) PT3209647T (ru)
RS (1) RS60737B1 (ru)
SG (1) SG11201702980QA (ru)
SI (1) SI3209647T1 (ru)
TN (1) TN2017000157A1 (ru)
UA (1) UA119794C2 (ru)
WO (1) WO2016065028A1 (ru)
ZA (1) ZA201702737B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN110036003B (zh) * 2016-10-25 2021-10-29 苏州晶云药物科技股份有限公司 Ap26113的新晶型及其制备方法
CN110520110A (zh) * 2017-03-08 2019-11-29 阿瑞雅德制药公司 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂
WO2019148789A1 (zh) * 2018-02-02 2019-08-08 苏州科睿思制药有限公司 布格替尼的晶型及其制备方法
EP3752132B1 (en) 2018-02-13 2021-12-08 Sandoz AG Pharmaceutical composition of brigatinib
WO2019182936A1 (en) 2018-03-19 2019-09-26 Ariad Pharmaceuticals, Inc. Methods of treating cancer in pediatric patients
WO2020099483A1 (en) 2018-11-15 2020-05-22 Sandoz Ag Crystalline forms of brigatinib
US20220242811A1 (en) * 2019-05-21 2022-08-04 Jiangsu ForeFront Pharmaceutical Co., Ltd Crystal form of treprostinil sodium salt and preparation method therefor
CN112047978A (zh) * 2019-06-05 2020-12-08 北京赛思源生物医药技术有限公司 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺新晶型
CN111138492B (zh) * 2020-01-06 2022-08-02 沈阳药科大学 Alk抑制剂布格替尼的制备方法
CN116234556A (zh) * 2020-12-18 2023-06-06 江苏豪森药业集团有限公司 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用
US20230015697A1 (en) * 2021-07-13 2023-01-19 Citrix Systems, Inc. Application programming interface (api) authorization
CN115154473A (zh) * 2022-08-04 2022-10-11 中国人民解放军陆军特色医学中心 布格替尼作为axl、c-met、st3gal4抑制剂的新应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
BE758350A (fr) * 1969-12-30 1971-05-03 Pfizer Procede de fabrication des sels mono- et bi-metalliques alcalins de l'alpha-carboxybenzylpenicilline
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE69427469T2 (de) * 1993-03-12 2001-10-31 Upjohn Co Kristallines ceftiofur (freie säure)
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP2001519346A (ja) 1997-10-07 2001-10-23 シェーリング コーポレイション 抗真菌性結晶性多形物
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ME00412B (me) 2001-06-22 2011-10-10 Boehringer Ingelheim Pharma Kristalni antiholinergik , postupak za njegovo pripremanje i njegova primjena u proizvodnji lijeka
CA2457642C (en) * 2001-09-26 2009-01-06 Merck & Co., Inc. Crystalline forms of ertapenem sodium
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
PL1660458T3 (pl) 2003-08-15 2012-07-31 Novartis Ag 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
CA2723961C (en) 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
EP3453708B8 (en) 2010-12-17 2022-03-16 Novartis AG Process for the preparation of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine di-hydrochloride

Also Published As

Publication number Publication date
US20180037597A1 (en) 2018-02-08
DK3209647T3 (da) 2020-08-24
US11427605B2 (en) 2022-08-30
LT3209647T (lt) 2020-09-25
CY1123295T1 (el) 2020-11-25
CN111888368B (zh) 2024-02-02
MX2017005120A (es) 2018-02-12
WO2016065028A1 (en) 2016-04-28
UA119794C2 (uk) 2019-08-12
JP2020063276A (ja) 2020-04-23
IL251818A0 (en) 2017-06-29
AU2015335950B2 (en) 2018-01-25
CN107108559A (zh) 2017-08-29
RS60737B1 (sr) 2020-09-30
IL251818B (en) 2021-01-31
HUE051693T2 (hu) 2021-03-29
US20200010493A1 (en) 2020-01-09
SG11201702980QA (en) 2017-05-30
CA2965169A1 (en) 2016-04-28
CA2965169C (en) 2021-11-16
MY192216A (en) 2022-08-09
KR20170072905A (ko) 2017-06-27
PT3209647T (pt) 2020-09-10
SI3209647T1 (sl) 2021-01-29
ZA201702737B (en) 2018-12-19
NZ730940A (en) 2021-10-29
CR20170146A (es) 2017-08-10
EP3209647B1 (en) 2020-06-03
EP3209647A1 (en) 2017-08-30
JP2017535538A (ja) 2017-11-30
CN111888368A (zh) 2020-11-06
CN107108559B (zh) 2020-06-05
US10934317B2 (en) 2021-03-02
EP3760618A1 (en) 2021-01-06
KR102331856B1 (ko) 2021-11-29
CN111825717A (zh) 2020-10-27
ECSP17030878A (es) 2018-01-31
PE20171344A1 (es) 2017-09-13
US10385078B2 (en) 2019-08-20
PH12017500732A1 (en) 2017-10-09
IL279910A (en) 2021-03-01
AU2015335950A1 (en) 2017-05-04
US20240043457A1 (en) 2024-02-08
KR20210142781A (ko) 2021-11-25
CO2017004714A2 (es) 2017-10-31
ES2813726T3 (es) 2021-03-24
DOP2017000101A (es) 2017-06-30
EA035145B1 (ru) 2020-05-06
TN2017000157A1 (en) 2018-10-19
CL2017000979A1 (es) 2018-01-05
HRP20201343T1 (hr) 2020-11-27
JP6633072B2 (ja) 2020-01-22
US20210355146A1 (en) 2021-11-18
WO2016065028A8 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
DOP2016000271A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201790630A1 (ru) Способы получения рибозидов
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
EA201691582A1 (ru) Новые фармацевтические препараты
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EA201691493A1 (ru) Замещенные n-арилпиридиноны

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment